TLDRs; CSL shares fell after Macquarie downgraded the stock and cut its price target to A$188. China albumin pressure and rising competition in therapies are weighing on CSL’s medium-term growth outlook. CSL’s ongoing share buy-back signals confidence but has failed to offset broader negative market sentiment…
Source







and then